{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:39:23Z","timestamp":1792852763746,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11030-024-11024-2","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T04:17:10Z","timestamp":1731039430000},"page":"4131-4158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Structure-based design and synthesis of novel FXIa inhibitors targeting the S2' subsite for enhanced antithrombotic efficacy"],"prefix":"10.1007","volume":"29","author":[{"given":"Jie","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"11024_CR1","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/jth.12698","volume":"12","author":"GE Raskob","year":"2014","unstructured":"Raskob GE, Angchaisuksiri P, Blanco AN et al (2014) Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 12:1580\u20131590. https:\/\/doi.org\/10.1111\/jth.12698","journal-title":"J Thromb Haemost"},{"key":"11024_CR2","doi-asserted-by":"publisher","first-page":"10419","DOI":"10.1021\/acs.jmedchem.2c00442","volume":"65","author":"G Xu","year":"2022","unstructured":"Xu G, Liu Z, Wang X et al (2022) Discovery of potent and orally bioavailable pyridine N-oxide-based factor XIa inhibitors through exploiting nonclassical interactions. J Med Chem 65:10419\u201310440. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00442","journal-title":"J Med Chem"},{"key":"11024_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jama.2014.65","volume":"311","author":"PS Wells","year":"2014","unstructured":"Wells PS, Forgie MA, Rodger MA (2014) Treatment of venous thromboembolism. JAMA 311:717\u2013728. https:\/\/doi.org\/10.1001\/jama.2014.65","journal-title":"JAMA"},{"key":"11024_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1517\/13543776.2016.1154045","volume":"26","author":"RA Al-Horani","year":"2016","unstructured":"Al-Horani RA, Desai UR (2016) Factor XIa inhibitors: a review of the patent literature. Expert Opin Ther Pat 26:323\u2013345. https:\/\/doi.org\/10.1517\/13543776.2016.1154045","journal-title":"Expert Opin Ther Pat"},{"key":"11024_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11239-011-0599-0","volume":"32","author":"PC Wong","year":"2011","unstructured":"Wong PC, Crain EJ, Watson CA, Schumacher WA (2011) A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis 32:129\u2013137. https:\/\/doi.org\/10.1007\/s11239-011-0599-0","journal-title":"J Thromb Thrombolysis"},{"key":"11024_CR6","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","volume":"165","author":"AM Holbrook","year":"2005","unstructured":"Holbrook AM, Pereira JA, Labiris R et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095\u20131106. https:\/\/doi.org\/10.1001\/archinte.165.10.1095","journal-title":"Arch Intern Med"},{"key":"11024_CR7","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1161\/01.cir.103.24.2994","volume":"103","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Anand SS, Halperin JL, Fuster V (2001) Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation 103:2994\u20133018. https:\/\/doi.org\/10.1161\/01.cir.103.24.2994","journal-title":"Circulation"},{"key":"11024_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ejmech.2016.05.039","volume":"121","author":"NR Patel","year":"2016","unstructured":"Patel NR, Patel DV, Murumkar PR, Yadav MR (2016) Contemporary developments in the discovery of selective factor Xa inhibitors: a review. Eur J Med Chem 121:671\u2013698. https:\/\/doi.org\/10.1016\/j.ejmech.2016.05.039","journal-title":"Eur J Med Chem"},{"key":"11024_CR9","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A et al (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e44S-e88S. https:\/\/doi.org\/10.1378\/chest.11-2292","journal-title":"Chest"},{"key":"11024_CR10","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/jm0109513","volume":"45","author":"NH Hauel","year":"2002","unstructured":"Hauel NH, Nar H, Priepke H et al (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45:1757\u20131766. https:\/\/doi.org\/10.1021\/jm0109513","journal-title":"J Med Chem"},{"key":"11024_CR11","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"DJP Pinto","year":"2007","unstructured":"Pinto DJP, Orwat MJ, Koch S et al (2007) Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50:5339\u20135356. https:\/\/doi.org\/10.1021\/jm070245n","journal-title":"J Med Chem"},{"key":"11024_CR12","doi-asserted-by":"publisher","first-page":"7770","DOI":"10.1021\/jm501045e","volume":"57","author":"T Xue","year":"2014","unstructured":"Xue T, Ding S, Guo B et al (2014) Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor. J Med Chem 57:7770\u20137791. https:\/\/doi.org\/10.1021\/jm501045e","journal-title":"J Med Chem"},{"key":"11024_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/clc.22582","volume":"39","author":"F Urooj","year":"2016","unstructured":"Urooj F, Kulkarni A, Stapleton D, Kaluski E (2016) New oral anticoagulants in nonvalvular atrial fibrillation. Clin Cardiol 39:739\u2013746. https:\/\/doi.org\/10.1002\/clc.22582","journal-title":"Clin Cardiol"},{"key":"11024_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejmech.2018.01.067","volume":"146","author":"Z Xie","year":"2018","unstructured":"Xie Z, Tian Y, Lv X et al (2018) The selectivity and bioavailability improvement of novel oral anticoagulants: an overview. Eur J Med Chem 146:299\u2013317. https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.067","journal-title":"Eur J Med Chem"},{"key":"11024_CR15","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","volume":"35","author":"CH Yeh","year":"2015","unstructured":"Yeh CH, Hogg K, Weitz JI (2015) Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol 35:1056\u20131065. https:\/\/doi.org\/10.1161\/ATVBAHA.115.303397","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"11024_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ckj\/sfu080","volume":"7","author":"S Hughes","year":"2014","unstructured":"Hughes S, Szeki I, Nash MJ, Thachil J (2014) Anticoagulation in chronic kidney disease patients: the practical aspects. Clin Kidney J 7:442\u2013449. https:\/\/doi.org\/10.1093\/ckj\/sfu080","journal-title":"Clin Kidney J"},{"key":"11024_CR17","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/jth.15700","volume":"20","author":"S Heitmeier","year":"2022","unstructured":"Heitmeier S, Visser M, Tersteegen A et al (2022) Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost 20:1400\u20131411. https:\/\/doi.org\/10.1111\/jth.15700","journal-title":"J Thromb Haemost"},{"key":"11024_CR18","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1002\/med.21503","volume":"38","author":"RA Al-Horani","year":"2018","unstructured":"Al-Horani RA, Afosah DK (2018) Recent advances in the discovery and development of factor XI\/XIa inhibitors. Med Res Rev 38:1974\u20132023. https:\/\/doi.org\/10.1002\/med.21503","journal-title":"Med Res Rev"},{"key":"11024_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jth.15126","volume":"19","author":"JC Fredenburgh","year":"2021","unstructured":"Fredenburgh JC, Weitz JI (2021) New anticoagulants: Moving beyond the direct oral anticoagulants. J Thromb Haemost 19:20\u201329. https:\/\/doi.org\/10.1111\/jth.15126","journal-title":"J Thromb Haemost"},{"key":"11024_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","volume":"3","author":"X Wang","year":"2005","unstructured":"Wang X, Cheng Q, Xu L et al (2005) Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 3:695\u2013702. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01236.x","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"11024_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1538-7836.2009.03395.x","volume":"7","author":"U Seligsohn","year":"2009","unstructured":"Seligsohn U (2009) Factor XI deficiency in humans. J Thromb Haemost 7(Suppl 1):84\u201387. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03395.x","journal-title":"J Thromb Haemost"},{"key":"11024_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1160\/TH10-05-0307","volume":"105","author":"O Salomon","year":"2011","unstructured":"Salomon O, Steinberg DM, Zucker M et al (2011) Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 105:269\u2013273. https:\/\/doi.org\/10.1160\/TH10-05-0307","journal-title":"Thromb Haemost"},{"key":"11024_CR23","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","volume":"111","author":"O Salomon","year":"2008","unstructured":"Salomon O, Steinberg DM, Koren-Morag N et al (2008) Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 111:4113\u20134117. https:\/\/doi.org\/10.1182\/blood-2007-10-120139","journal-title":"Blood"},{"key":"11024_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1046\/j.1538-7836.2003.00195.x","volume":"1","author":"O Salomon","year":"2003","unstructured":"Salomon O, Steinberg DM, Dardik R et al (2003) Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 1:658\u2013661. https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00195.x","journal-title":"J Thromb Haemost"},{"key":"11024_CR25","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1021\/acs.jmedchem.2c02130","volume":"66","author":"Z Xie","year":"2023","unstructured":"Xie Z, Meng Z, Yang X et al (2023) Factor XIa inhibitors in anticoagulation therapy: Recent advances and perspectives. J Med Chem 66:5332\u20135363. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c02130","journal-title":"J Med Chem"},{"key":"11024_CR26","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/jth.15439","volume":"19","author":"D Thomas","year":"2021","unstructured":"Thomas D, Kanefendt F, Schwers S et al (2021) First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J Thromb Haemost 19:2407\u20132416. https:\/\/doi.org\/10.1111\/jth.15439","journal-title":"J Thromb Haemost"},{"key":"11024_CR27","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","volume":"65","author":"AK Dilger","year":"2022","unstructured":"Dilger AK, Pabbisetty KB, Corte JR et al (2022) Discovery of Milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy. J Med Chem 65:1770\u20131785. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00613","journal-title":"J Med Chem"},{"key":"11024_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.821363","volume":"13","author":"R Chen","year":"2022","unstructured":"Chen R, Guan X, Hu P et al (2022) First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of SHR2285, a small-molecule factor XIa inhibitor in healthy subjects. Front Pharmacol 13:821363. https:\/\/doi.org\/10.3389\/fphar.2022.821363","journal-title":"Front Pharmacol"},{"key":"11024_CR29","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1111\/bcp.14732","volume":"87","author":"D Beale","year":"2021","unstructured":"Beale D, Dennison J, Boyce M et al (2021) ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study. Br J Clin Pharmacol 87:3177\u20133189. https:\/\/doi.org\/10.1111\/bcp.14732","journal-title":"Br J Clin Pharmacol"},{"key":"11024_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000196","volume":"2","author":"CV Pollack Jr","year":"2020","unstructured":"Pollack CV Jr, Kurz MA, Hayward NJ (2020) EP-7041, a factor XIa inhibitor as a potential antithrombotic strategy in extracorporeal membrane oxygenation: A brief report. Crit Care Explor 2:e0196. https:\/\/doi.org\/10.1097\/CCE.0000000000000196","journal-title":"Crit Care Explor"},{"key":"11024_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14728214.2019.1591368","volume":"24","author":"O Sz\u00e9kely","year":"2019","unstructured":"Sz\u00e9kely O, Borgi M, Lip GYH (2019) Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation. Expert Opin Emerg Drugs 24:55\u201361. https:\/\/doi.org\/10.1080\/14728214.2019.1591368","journal-title":"Expert Opin Emerg Drugs"},{"key":"11024_CR32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1021\/jm401670x","volume":"57","author":"ML Quan","year":"2014","unstructured":"Quan ML, Wong PC, Wang C et al (2014) Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors. J Med Chem 57:955\u2013969. https:\/\/doi.org\/10.1021\/jm401670x","journal-title":"J Med Chem"},{"key":"11024_CR33","doi-asserted-by":"publisher","first-page":"7226","DOI":"10.1021\/acs.jmedchem.0c00464","volume":"63","author":"W Yang","year":"2020","unstructured":"Yang W, Wang Y, Lai A et al (2020) Discovery of a high affinity, orally bioavailable macrocyclic FXIa inhibitor with antithrombotic activity in preclinical species. J Med Chem 63:7226\u20137242. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00464","journal-title":"J Med Chem"},{"key":"11024_CR34","doi-asserted-by":"publisher","first-page":"8088","DOI":"10.1021\/acs.jmedchem.0c00279","volume":"63","author":"E Lorthiois","year":"2020","unstructured":"Lorthiois E, Roache J, Barnes-Seeman D et al (2020) Structure-based design and preclinical characterization of selective and orally bioavailable factor XIa inhibitors: Demonstrating the power of an integrated S1 protease family approach. J Med Chem 63:8088\u20138113. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00279","journal-title":"J Med Chem"},{"key":"11024_CR35","doi-asserted-by":"publisher","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","volume":"66","author":"S Roehrig","year":"2023","unstructured":"Roehrig S, Ackerstaff J, Jim\u00e9nez N\u00fa\u00f1ez E et al (2023) Design and preclinical characterization program toward Asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders. J Med Chem 66:12203\u201312224. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00795","journal-title":"J Med Chem"},{"key":"11024_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.15420\/ecr.2023.50","volume":"19","author":"M Komiyama","year":"2024","unstructured":"Komiyama M, Iguchi M, Wada H et al (2024) What is the future position of factor XIa inhibitors for patients with atrial fibrillation? Eur Cardiol 19:10. https:\/\/doi.org\/10.15420\/ecr.2023.50","journal-title":"Eur Cardiol"},{"key":"11024_CR37","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","volume":"431","author":"M Schaefer","year":"2019","unstructured":"Schaefer M, Buchmueller A, Dittmer F et al (2019) Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI. J Mol Biol 431:4817\u20134833. https:\/\/doi.org\/10.1016\/j.jmb.2019.09.008","journal-title":"J Mol Biol"},{"key":"11024_CR38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.carres.2008.11.007","volume":"344","author":"AV Gudmundsdottir","year":"2009","unstructured":"Gudmundsdottir AV, Paul CE, Nitz M (2009) Stability studies of hydrazide and hydroxylamine-based glycoconjugates in aqueous solution. Carbohydr Res 344:278\u2013284. https:\/\/doi.org\/10.1016\/j.carres.2008.11.007","journal-title":"Carbohydr Res"},{"key":"11024_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113437","volume":"220","author":"Y Lei","year":"2021","unstructured":"Lei Y, Zhang B, Zhang Y et al (2021) Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment. Eur J Med Chem 220:113437. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113437","journal-title":"Eur J Med Chem"},{"key":"11024_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jsb.2019.03.001","volume":"206","author":"JR Partridge","year":"2019","unstructured":"Partridge JR, Choy RM, Silva-Garcia A et al (2019) Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition. J Struct Biol 206:170\u2013182. https:\/\/doi.org\/10.1016\/j.jsb.2019.03.001","journal-title":"J Struct Biol"},{"key":"11024_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112137","volume":"190","author":"Z Xie","year":"2020","unstructured":"Xie Z, Li Z, Shao Y et al (2020) Discovery and development of plasma kallikrein inhibitors for multiple diseases. Eur J Med Chem 190:112137. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112137","journal-title":"Eur J Med Chem"},{"key":"11024_CR42","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/jth.15700","volume":"20","author":"S Heitmeier","year":"2022","unstructured":"Heitmeier S, Visser M, Tersteegen A et al (2022) Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost 20:1400\u20131411","journal-title":"J Thromb Haemost"},{"key":"11024_CR43","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.3389\/fmicb.2018.02625","volume":"9","author":"Q Ma","year":"2018","unstructured":"Ma Q, Zhang Y, Qu Y (2018) Biodegradation and biotransformation of indole: advances and perspectives. Front Microbiol 9:2625. https:\/\/doi.org\/10.3389\/fmicb.2018.02625","journal-title":"Front Microbiol"},{"key":"11024_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107556","volume":"151","author":"J Wu","year":"2024","unstructured":"Wu J, Wang X, Yao Y et al (2024) Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1\/HDAC-1 inhibitors. Bioorg Chem 151:107556. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107556","journal-title":"Bioorg Chem"},{"key":"11024_CR45","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.thromres.2011.02.004","volume":"127","author":"CW Kim","year":"2011","unstructured":"Kim CW, Yun JW, Bae IH et al (2011) Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100\u00ae and Multiplate\u00ae whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo. Thromb Res 127:565\u2013570. https:\/\/doi.org\/10.1016\/j.thromres.2011.02.004","journal-title":"Thromb Res"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-11024-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:04:03Z","timestamp":1758719043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-11024-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["11024"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-11024-2","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}